Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells
By: Jana Hřebačková, Jitka Poljaková, Tomáš Eckschlager, Jan Hraběta, Pavel Procházka, Svatopluk Smutný and Marie Stiborová
Open Access
|Sep 2009References
- Batty N, Malouf GG, Issa JP. (2009). Histone deacetylase inhibitors as anti-neoplastic agents.: 192-200.
- Blaheta RA, Cinatl J Jr. (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug.: 492-511.
- Bolden JE, Peart MJ, Johnstone RW. (2006). Anticancer activities of histone deacetylase inhibitors.: 769-784.
- Bort R, Gomez-Lechon MJ, Castell JV, Jover R. (2004). Role of hepatocyte nuclear factor 3 gamma in the expression of human CYP2C genes.: 63-72.
- Brodeur GM. (2003). Neuroblastoma: biological insights into a clinical enigma.: 203-216.
- Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, Ulrichova J, Anzenbacher P, Pavek P. (2007). Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.: 1032-1041.
- Cinatl J Jr., Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B. (1996). Antitumor activity of sodium valproate in cultures of human neuroblastoma cells.: 766-773.
- Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. (2008). Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.: 657-668.
- Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. (2008). Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors.: 206-222.
- Fisher JE, Nau H, Löscher W. (1991). Alterations in the renal excretion of valproate and its metabolites after chronic treatment.: 146-150.
- Furchert SE, Lanvers-Kaminsky C, Juürgens H, Jung M, Loidl A, Frühwald MC. (2007). Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.: 787-1794.
- Hooven LA, Mahadevan B, Keshava C, Johns C, Pereira C, Desai D, Amin S, Weston A, Baird WM. (2005). Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.: 1283-1287.
- Hopkins-Donaldson S, Yan P, Bourloud KB, Muhlethaler A, Bodmer JL and Gross N. (2002). Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase-independent in N-type cells.: 6132-6137.
- Isojärvi JI, Turkka J, Pakarinen AJ, Kotila M, Rättyä J, Myllylä VV. (2001). Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy.: 930-934.
- Kiang TK, Ho PC, Anari MR, Tong V, Abbott FS, Chang TK. (2006). Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.: 261-271.
- Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. (2005). Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.: 3815-3822.
- Maris JM, Mathay KK. (1999). Molecular biology of neuroblastomas.: 2264-2279.
- Marks PA, Miller T, Richon VM. (2003). Histone deacetylases.: 344-351.
- Marks PA, Richon VM, Miller T, Kelly WK. (2004). Histone deacetylase inhibitors.: 137-168.
- Michaelis M, Doerr HW, Cinatl J Jr. (2007). Valproic acid as anti-cancer drug.: 3378-3393.
- Michaelis M, Suhan T, Cinatl J, Driever PH, Cinatl J Jr. (2004). Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo.: 1795-1799.
- Morgenstern BZ, Krivoshik AP, Rodriguez V and Anderson PM. (2004). Wilms' tumor and neuroblastoma.: 78-85.
- Myasoedova KN. (2008). New findings in studies of cytochromes P450.: 965-969.
- Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, Strauss JF 3rd, McAllister JM. (2004). Valproate potentiates androgen biosynthesis in human ovarian theca cells.: 799-808.
- Poljakova J, Eckschlager T, Hrabeta J, Hrebackova J, Smutny S, Frei E, Martinek V, Kizek R, Stiborova M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.: 1466-1479.
- Rogiers V, Akrawi M, Vercruysse A, Phillips IR, Shephard EA. (1995). Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases.: 337-343.
- Rogiers V, Callaerts A, Vercruysse A, Akrawi M, Shephard E, Phillips I. (1992). Effects of valproate on xenobiotic biotransformation in rat liver. In vivo and in vitro experiments.: 127-131.
- Santini V, Gozzini A, Ferrari G. (2007). Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.: 383-393.
- Servidei T, Morosetti R, Ferlini C, Cusano G, Scambia G, Mastrangelo R, Koeffler HP. (2004). The cellular response to PPARgamma ligands is related to the phenotype of neuroblastoma cell lines.: 345-354.
- Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, Tavares de Almeida I. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review.: 205-216.
- Snykers S, Vanhaecke T, De Becker A, Papeleu P, Vinken M, Van Riet I, Rogiers V. (2007). Chromatin remodeling agent trichostatin A: a key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow.: 24-39.
- Van Lint C, Emiliani S, Verdin E. (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.: 245-253.
- Voigt A, Hartmann P and Zintl F. (2000). Differentiation, proliferation and adhesion of human neuroblastoma cells after treatment with retinoic acid.: 423-440.
- Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. (2001). In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).: 547-553.
Language: English
Page range: 205 - 210
Published on: Sep 24, 2009
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Related subjects:
© 2009 Jana Hřebačková, Jitka Poljaková, Tomáš Eckschlager, Jan Hraběta, Pavel Procházka, Svatopluk Smutný, Marie Stiborová, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.